The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours
- PMID: 6420159
- DOI: 10.1016/0277-5379(84)90045-2
The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours
Abstract
The concentrations of tamoxifen and two of its metabolites, N-desmethyltamoxifen and 4'-hydroxytamoxifen (metabolite B), have been measured in rat plasma and DMBA-induced tumours using gas chromatography-mass spectrometry. At a dose of 100 micrograms/day all three compounds produced tumour regression and, in the case of tamoxifen, the number and extent of regressions and the inhibition of new tumours were dependent upon dosage. No correlation was observed, however, between tumour regression and the concentrations of tamoxifen or N-desmethyltamoxifen in the plasma of individual animals. When tamoxifen, N-desmethyltamoxifen and metabolite B were measured in oestrogen-receptor-positive tumours a correlation was found between reduction in tumour and the tamoxifen concentration in cytosol fractions. The concentrations of all three compounds in both nuclear and cytosol fractions were higher than could be accounted for by binding to the oestrogen receptor. The mechanistic significance of these high values is, at present, unclear.
Similar articles
-
Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.Cancer Chemother Pharmacol. 1995;37(1-2):7-13. doi: 10.1007/BF00685623. Cancer Chemother Pharmacol. 1995. PMID: 7497599
-
Anti-oestrogen action in experimental breast cancer.Recent Results Cancer Res. 1980;71:30-44. doi: 10.1007/978-3-642-81406-8_8. Recent Results Cancer Res. 1980. PMID: 6768113 Review. No abstract available.
-
The effect of pregnant mares serum gonadotrophin on the response of DMBA induced rat mammary tumours to tamoxifen or oestrogen.Eur J Cancer Clin Oncol. 1989 Dec;25(12):1843-50. doi: 10.1016/0277-5379(89)90357-x. Eur J Cancer Clin Oncol. 1989. PMID: 2517258
-
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.Breast Cancer Res Treat. 1983;3 Suppl:S73-86. doi: 10.1007/BF01855131. Breast Cancer Res Treat. 1983. PMID: 6423014 Review.
-
Reduction of estrogen and prolactin receptors in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor by high doses of estrogen.Jpn J Surg. 1987 Sep;17(5):395-401. doi: 10.1007/BF02470640. Jpn J Surg. 1987. PMID: 3123757
Cited by
-
Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.Cancer Chemother Pharmacol. 1995;37(1-2):7-13. doi: 10.1007/BF00685623. Cancer Chemother Pharmacol. 1995. PMID: 7497599
-
The effects of tamoxifen on the osteopenia induced by sciatic neurotomy in the rat: a histomorphometric study.Calcif Tissue Int. 1988 Dec;43(6):383-8. doi: 10.1007/BF02553283. Calcif Tissue Int. 1988. PMID: 3146428
-
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.Breast Cancer Res Treat. 1993 Dec;28(3):241-50. doi: 10.1007/BF00666585. Breast Cancer Res Treat. 1993. PMID: 8018953 Clinical Trial.
-
Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.Br J Cancer. 1987 May;55(5):509-12. doi: 10.1038/bjc.1987.103. Br J Cancer. 1987. PMID: 3606944 Free PMC article.